Fibrin Metabolism in Patients with Acute Myocardial Infarction During and After Treatment with Tissue-Type Plasminogen Activator
暂无分享,去创建一个
[1] E. Seifried,et al. FIBRIN DEGRADATION PRODUCTS ARE NOT SPECIFIC MARKERS FOR THROMBOLYSIS IN MYOCARDIAL INFARCTION , 1987, The Lancet.
[2] A. Ross,et al. Reinfarction, recurrent angina, and reocclusion after thrombolytic therapy. , 1987, Circulation.
[3] K. Friedman,et al. Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator. , 1987, The Journal of clinical investigation.
[4] S. Sherry. Recombinant tissue plasminogen activator (rt-PA): is it the thrombolytic agent of choice for an evolving acute myocardial infarction? , 1987, The American journal of cardiology.
[5] A. Jaffe,et al. Relationship between elevated plasma levels of crosslinked fibrin degradation products (XL-FDP) and the clinical presentation of patients with myocardial infarction. , 1987, Thrombosis research.
[6] P. Ludbrook,et al. Sustained Fibrinolysis After Administration of t-PA Despite Its Short Half-Life in the Circulation , 1987, Thrombosis and Haemostasis.
[7] C. Francis,et al. Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction. , 1986, Circulation.
[8] M. Mohler,et al. D-Phe-Pro-Arg-Chloromethylketone: Its Potential Use in Inhibiting the Formation of In Vitro Artifacts in Blood Collected During Tissue-Type Plasminogen Activator Thrombolytic Therapy , 1986, Thrombosis and Haemostasis.
[9] P. Shah,et al. Elevated serum D dimer: a degradation product of cross-linked fibrin (XDP) after intravenous streptokinase during acute myocardial infarction. , 1986, Journal of the American College of Cardiology.
[10] D. Collen,et al. A monoclonal antibody preventing binding of tissue-type plasminogen activator to fibrin: useful to monitor fibrinogen breakdown during t-PA infusion. , 1986, Blood.
[11] D. Collen,et al. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. , 1985, The Journal of pharmacology and experimental therapeutics.
[12] W. Ganz,et al. The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.
[13] M. Simoons,et al. IMPROVED SURVIVAL AFTER EARLY THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION A Randomised Trial by the Interuniversity Cardiology Institute in The Netherlands , 1985, The Lancet.
[14] D. Rylatt,et al. Serum crosslinked fibrin (XDP) and fibrinogen/fibrin degradation products (FDP) in disorders associated with activation of the coagulation or fibrinolytic systems , 1985, British journal of haematology.
[15] A. Gallino,et al. Fibrin formation and platelet aggregation in patients with severe coronary artery disease: relationship with the degree of myocardial ischemia. , 1985, Circulation.
[16] P. Gaffney,et al. Unreliability of Current Serum Fibrin Degradation Product (FDP) Assays , 1985, Thrombosis and Haemostasis.
[17] A. Jaffe,et al. Fibrinopeptide A: a marker of acute coronary thrombosis. , 1985, Circulation.
[18] L. Fleisher,et al. Effect of heparin bonding on catheter-induced fibrin formation and platelet activation. , 1984, Circulation.
[19] D. Rylatt,et al. Measurement of cross linked fibrin derivatives in plasma: an immunoassay using monoclonal antibodies. , 1984, Journal of clinical pathology.
[20] A. Haeberli,et al. Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction. , 1984, Circulation.
[21] B. Kudryk,et al. A monoclonal antibody with ability to distinguish between NH2-terminal fragments derived from fibrinogen and fibrin. , 1983, Molecular immunology.
[22] D. Rylatt,et al. An immunoassay for human D dimer using monoclonal antibodies. , 1983, Thrombosis research.
[23] D. Rylatt,et al. Measurement of Crosslinked Fibrin Degradation Products – An Immunoassay Using Monoclonal Antibodies , 1983, Thrombosis and Haemostasis.
[24] W. Nieuwenhuizen,et al. Catabolism of Purified Rat Fibrin(ogen) Plasmin Degradation Products in Rats , 1982, Thrombosis and Haemostasis.
[25] R. Canfield,et al. Sequence of fibrinogen proteolysis and platelet release after intrauterine infusion of hypertonic saline. , 1979, The Journal of clinical investigation.
[26] B. Blombäck,et al. A two-step fibrinogen–fibrin transition in blood coagulation , 1978, Nature.
[27] J. Hirsh,et al. Plasma fibrinopeptide A levels in symptomatic venous thromboembolism. , 1978, Blood.
[28] C. Kockum. Radioimmunoassay of fibrinopeptide A-clinical applications. , 1976, Thrombosis research.
[29] R. Canfield,et al. Measurement of fibrinopeptide A in human blood. , 1974, The Journal of clinical investigation.
[30] R. Doolittle,et al. - cross-linking sites in human and bovine fibrin. , 1971, Biochemistry.
[31] B. Kudryk,et al. Specificity of a monoclonal antibody for the NH2-terminal region of fibrin. , 1984, Molecular immunology.
[32] H. Johnsson,et al. Fibrinopeptide a (FPA) in patients with acute myocardial infarction. , 1979, Thrombosis research.